Prioritizing mutational profiling for targeted therapy of lung adenocarcinoma

The Lung Cancer Mutation Consortium (LCMC) was launched as a cross-institutional effort to prospectively follow non-small cell lung cancer (NSCLC) patients across sixteen centers in the US, with a focus on genomic mutation profiles, in an effort to improve the selection of effective therapeutic courses (1).